The potential for novel drugs to be used across many types of diseases brings tremendous opportunity for biopharmaceutical companies. New product planning teams play a vital role in ensuring that these treatments deliver their full value not just to the companies that produce them but also to the patients who can benefit from them. Join us for a session on maximizing the lifetime value of drugs with multi-indication potential. We will discuss the pressures reshaping indication prioritization and sequencing, research on value-maximizing strategies and the ways companies can evolve new product planning—from capabilities and operating models to AI and machine learning applications.
